For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
As of close of business last night, Transmedics Group Inc’s stock clocked out at $72.55, down -7.78% from its previous closing price of $78.67. In other words, the price has decreased by -$7.78 from its previous closing price. On the day, 3.37 million shares were traded. TMDX stock price reached its highest trading level at $77.3199 during the session, while it also had its lowest trading level at $72.34.
Ratios:
To gain a deeper understanding of TMDX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.33 and its Current Ratio is at 8.20. In the meantime, Its Debt-to-Equity ratio is 2.47 whereas as Long-Term Debt/Eq ratio is at 2.46.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, JP Morgan on December 17, 2024, Downgraded its rating to Neutral and sets its target price to $75 from $116 previously.
Oppenheimer reiterated its Outperform rating for the stock on October 29, 2024, while the target price for the stock was revised from $200 to $125.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 02 ’24 when Khayal Tamer I sold 1,084 shares for $86.40 per share. The transaction valued at 93,658 led to the insider holds 20,843 shares of the business.
Khayal Tamer I sold 1,458 shares of TMDX for $131,278 on Nov 11 ’24. The Chief Commercial Officer now owns 20,843 shares after completing the transaction at $90.04 per share. On Nov 05 ’24, another insider, Basile Edward M, who serves as the Director of the company, sold 6,750 shares for $83.55 each. As a result, the insider received 563,994 and left with 732 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TMDX now has a Market Capitalization of 2434886912 and an Enterprise Value of 2622940160. As of this moment, Transmedics’s Price-to-Earnings (P/E) ratio for their current fiscal year is 77.73, and their Forward P/E ratio for the next fiscal year is 49.38. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.07 while its Price-to-Book (P/B) ratio in mrq is 11.60. Its current Enterprise Value per Revenue stands at 6.54 whereas that against EBITDA is 51.291.
Stock Price History:
Over the past 52 weeks, TMDX has reached a high of $177.37, while it has fallen to a 52-week low of $58.27. The 50-Day Moving Average of the stock is -4.67%, while the 200-Day Moving Average is calculated to be -39.62%.
Shares Statistics:
It appears that TMDX traded 1.88M shares on average per day over the past three months and 1979810 shares per day over the past ten days. A total of 33.56M shares are outstanding, with a floating share count of 32.43M. Insiders hold about 3.39% of the company’s shares, while institutions hold 109.86% stake in the company. Shares short for TMDX as of 1734048000 were 8639718 with a Short Ratio of 4.59, compared to 1731628800 on 8975940. Therefore, it implies a Short% of Shares Outstanding of 8639718 and a Short% of Float of 31.309998.
